Literature DB >> 27587380

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Nicola Gökbuget1, Hervè Dombret2, Jose-Maria Ribera3, Adele K Fielding4, Anjali Advani5, Renato Bassan6, Victoria Chia7, Michael Doubek8, Sebastian Giebel9, Dieter Hoelzer10, Norbert Ifrah11, Aaron Katz7, Michael Kelsh7, Giovanni Martinelli12, Mireia Morgades3, Susan O'Brien13, Jacob M Rowe14, Julia Stieglmaier15, Martha Wadleigh16, Hagop Kantarjian13.   

Abstract

Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients with Ph-negative relapsed/refractory B-precursor acute lymphoblastic leukemia diagnosed between 1990-2013 was conducted using data reflecting the standard of care from 11 study groups and large centers in Europe and the United States. Outcomes included complete remission, overall survival, and realization of stem cell transplantation after salvage treatment. The overall complete remission rate after first salvage was 40%, ranging from 35%-41% across disease status categories (primary refractory, relapsed with or without prior transplant), and was lower after second (21%) and third or greater (11%) salvage. The overall complete remission rate was higher for patients diagnosed from 2005 onward (45%, 95% CI: 39%-50%). One- and three-year survival rates after first, second, and third or greater salvage were 26% and 11%, 18% and 6%, and 15% and 4%, respectively, and rates were 2%-5% higher among patients diagnosed from 2005. Prognostic factors included younger age, longer duration of first remission, and lower white blood cell counts at primary diagnosis. This large dataset can provide detailed reference outcomes for patients with relapsed/refractory Ph-negative B-precursor acute lymphoblastic leukemia. clinicaltrials.gov identifier: 02003612. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2016        PMID: 27587380      PMCID: PMC5479605          DOI: 10.3324/haematol.2016.144311

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  20 in total

1.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

Authors:  Sima Jeha; Paul S Gaynon; Bassem I Razzouk; Janet Franklin; Richard Kadota; Violet Shen; Lori Luchtman-Jones; Michael Rytting; Lisa R Bomgaars; Susan Rheingold; Kim Ritchey; Edythe Albano; Robert J Arceci; Stewart Goldman; Timothy Griffin; Arnold Altman; Bruce Gordon; Laurel Steinherz; Steven Weitman; Peter Steinherz
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.

Authors:  D A Thomas; H Kantarjian; T L Smith; C Koller; J Cortes; S O'Brien; F J Giles; J Gajewski; S Pierce; M J Keating
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

4.  Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone.

Authors:  Seoyeon Choi; Michelle J Henderson; Edward Kwan; Alex H Beesley; Rosemary Sutton; Anita Y Bahar; Jodie Giles; Nicola C Venn; Luciano Dalla Pozza; David L Baker; Glenn M Marshall; Ursula R Kees; Michelle Haber; Murray D Norris
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

5.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

6.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Authors:  Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien
Journal:  Lancet Oncol       Date:  2012-02-21       Impact factor: 41.316

7.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Authors:  Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Jose Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W Deininger; Charles A Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.

Authors:  R Simon; R W Makuch
Journal:  Stat Med       Date:  1984 Jan-Mar       Impact factor: 2.373

9.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

Authors:  E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

Review 10.  Relapsed childhood acute lymphoblastic leukaemia.

Authors:  Deepa Bhojwani; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

View more
  52 in total

1.  Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.

Authors:  Inaam Bashir Hassan; Jorgen Kristensen; Khalid Al Qawasmeh; Arif Alam
Journal:  Int J Hematol       Date:  2018-06-27       Impact factor: 2.490

2.  Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient.

Authors:  J Yu; Y Hu; C Pu; Z Liang; Q Cui; H Zhang; Y Luo; J Shi; A Jin; L Xiao; Z Wu; H Huang
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

3.  Historical Controls?

Authors:  Paul S Gaynon
Journal:  Haematologica       Date:  2017-02-28       Impact factor: 9.941

4.  Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Authors:  Patrice Chevallier; Sylvain Chantepie; Francoise Huguet; Emmanuel Raffoux; Xavier Thomas; Thibaut Leguay; Tony Marchand; Francoise Isnard; Aude Charbonnier; Sébastien Maury; Maria-Pilar Gallego-Hernanz; Nelly Robillard; Thierry Guillaume; Pierre Peterlin; Alice Garnier; Fanny Rialland; Claire Le Houerou; David M Goldenberg; William A Wegener; Marie-C Béné; Hervé Dombret
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

Review 5.  The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.

Authors:  Edward Cox; Ros Wade; Mathilde Peron; Kristina Charlotte Dietz; Alison Eastwood; Stephen Palmer; Susan Griffin
Journal:  Pharmacoeconomics       Date:  2019-09       Impact factor: 4.981

6.  Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.

Authors:  Klaus Wethmar; Svenja Matern; Eva Eßeling; Linus Angenendt; Heike Pfeifer; Monika Brüggemann; Patrick Stelmach; Simon Call; Jörn C Albring; Jan-Henrik Mikesch; Christian Reicherts; Christoph Groth; Christoph Schliemann; Wolfgang E Berdel; Georg Lenz; Matthias Stelljes
Journal:  Bone Marrow Transplant       Date:  2020-01-30       Impact factor: 5.483

7.  Blinatumomab bridges the gap between leukemia and immunity.

Authors:  Takahiro Yamazaki; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-07-31       Impact factor: 8.110

8.  Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget; Hagop M Kantarjian; Monika Brüggemann; Anthony S Stein; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Françoise Rigal-Huguet; Mark Litzow; Susan O'Brien; Gerhard Zugmaier; Shan Gao; Dirk Nagorsen; Stephen J Forman; Max S Topp
Journal:  Blood Adv       Date:  2019-10-22

9.  Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

Authors:  N Toft; H Birgens; J Abrahamsson; L Griškevičius; H Hallböök; M Heyman; T W Klausen; Ó G Jónsson; K Palk; K Pruunsild; P Quist-Paulsen; G Vaitkeviciene; K Vettenranta; A Åsberg; T L Frandsen; H V Marquart; H O Madsen; U Norén-Nyström; K Schmiegelow
Journal:  Leukemia       Date:  2017-08-18       Impact factor: 11.528

10.  Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia.

Authors:  Alessandro Rambaldi; Francoise Huguet; Pavel Zak; Paul Cannell; Qui Tran; Janet Franklin; Max S Topp
Journal:  Blood Adv       Date:  2020-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.